AbCellera Biologics (ABCL) Cash from Financing Activities (2020 - 2026)

AbCellera Biologics has reported Cash from Financing Activities for 7 years, with the latest figure at $7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 20.47% year-over-year to $7.2 million; the trailing twelve-month figure through Mar 2026 stood at $15.3 million (down 3.8% YoY), and the FY2025 full-year result was $14.1 million, up 10.28% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $7.2 million, up from $4.1 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $7.4 million in Q3 2025, with the low at -$3.4 million in Q2 2025.
• Historically, Cash from Financing Activities has averaged $2.5 million across 5 years, with a median of $2.8 million in 2024.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 34994.74% — and 2025, when it tumbled 227.31%.
• AbCellera Biologics' Cash from Financing Activities stood at $349000.0 in 2022, then surged by 978.8% to $3.8 million in 2023, then gained by 10.01% to $4.1 million in 2024, then retreated by 0.65% to $4.1 million in 2025, then surged by 74.78% to $7.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $7.2 million (Q1 2026), $4.1 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.